Category: Optic neuritis

The US Food and Drug Administration has granted breakthrough therapy designation to privosegtor, an experimental treatment being developed by Oculis for people with acute optic neuritis, a common and potentially disabling manifestation of multiple sclerosis that can result in vision loss. Optic neuritis is caused by inflammation of the optic nerve and is estimated to…